

Meet The Professors Live: Clinical Investigators Provide Perspectives on Actual Cases of Patients with Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following bispecific antibodies is FDA approved for the management of relapsed/refractory (R/R) diffuse large B-cell lymphoma?
 - a. Epcoritamab
 - b. Glofitamab
 - c. Mosunetuzumab
 - d. Odronextamab
2. Polatumab vedotin with R-CHP (pola-R-CHP) demonstrated greater efficacy compared to R-CHOP in which of the following disease subgroups in the Phase III POLARIX trial?
 - a. ABC subtype
 - b. GCB subtype
 - c. Unclassified cell of origin
 - d. All of the above
3. Which of the following front-line therapies resulted in the highest levels of undetectable minimal residual disease for fit patients with chronic lymphocytic leukemia in the Phase III GAIA/CLL13 trial?
 - a. FCR
 - b. Venetoclax/rituximab
 - c. Venetoclax/obinutuzumab
 - d. Venetoclax/obinutuzumab/ibrutinib
4. What was the approximate overall response rate observed with pirtobrutinib in patients who had previously received another Bruton tyrosine kinase inhibitor for mantle cell lymphoma in the Phase I/II BRUIN study?
 - a. 25%
 - b. 40%
 - c. Greater than 55%
5. Which of the following best describes the mechanism of action of linvoseltamab, which is under investigation for patients with R/R multiple myeloma?
 - a. CD3 x BCMA bispecific antibody
 - b. CD8 x CD38 BCMA bispecific antibody
 - c. XPO1 inhibitor
 - d. AKT inhibitor